The effect of empagliflozin on cardiac systolic and diastolic functions in patients with type 2 diabetes mellitus and hypertension

Empagliflozin may positively affect subclinical left ventricle (LV) dysfunction.We aimed to investigate the effect of empagliflozin on cardiac systolic and diastolic functions in patients with Type 2 diabetes mellitus (DM) and hypertension.Sixty-three patients who underwent transthoracic echocardiography between October -2019 and June-2020, receiving at least one antihypertensive pill, and started empagliflozin treatment due to Type-2 DM were included in the study.Echocardiographic parameters like global longitudinal strain (GLS), left atrial volume index (Lavi), before and 6 months after empagliflozin treatment were compared.Patient's blood pressure (BP), waist circumference, body mass index (BMI), NT-proBNP and other blood parameters were examined.Of the 63 patients who participated in the study, 30 (47.6%) were male.There was an improvement in subclinical cardiac dysfunctions with the use of empagliflozin for 6 months.There was statistically significant difference in GLS ( 152.42 to 16.32.3,p<0.001),E/e' (10[8.5-11],10.5[9-12], p:0.01),Lavi (29.610.5to27.39.8,p<0.001)and 65.7,p<0.001).Significant improvement in GLS was associated with baseline BMI and NT -proBNP elevation.Also, the decrease in Lavi was found to be related to the initial NT-proBNP elevation.In addition, there were significant changes in patients BP (1357.9,1286.9,p-<0.001),diastolic BP (80.27.2, 78.66.6,p-value 0.012), waist circumference (1078.9,1049.1,p<0.001)and BMI (33.55.6;30.24.3;p<0.001).Empagliflozin treatment improved subclinical LV systolic and diastolic dysfunctions in patients with Type 2 DM and hypertension.The benefit of Empagliflozin may be associated with weight loss and decrease of NT -pro BNP as this improvement was more prominent in patients with high baseline BMI and NT -proBNP.